Sign In
Buy PGEN
$5.36
-0.0200 (-0.372%)
At Close: Jun 23, 2026
Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging
06:40am, Monday, 15'th Jun 2026
Meg Flippin, Benzinga Staff Writer Data reviewed by Dr. Helen Sabzevari at last week's Goldman Sachs healthcare conference suggests potential of extended surgical holidays for patients with RRP, a rar
Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?
03:45pm, Friday, 12'th Jun 2026
41,884 shares were sold in an open-market transaction for a total of ~$183,000 on May 28, 2026. The sale reduced direct holdings by 7.0%, from 596,419 shares to 554,535 shares, with no change to indir
Third annual RRP Awareness Day highlights the experiences of people living with recurrent respiratory papillomatosis and marks the next era following the first FDA-approved treatment for adults with R
Precigen, Inc. (PGEN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
11:38am, Monday, 08'th Jun 2026
Precigen, Inc. (PGEN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Precigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?
01:02pm, Monday, 01'st Jun 2026
Does Precigen, Inc. (PGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses
15 out of 18 complete responders, or 83%, demonstrated ongoing complete responses for at least 36 months without any additional treatment for RRP 5 complete responders have ongoing responses beyond 4
Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States
07:00am, Wednesday, 27'th May 2026
FDA grants orphan drug exclusivity for PAPZIMEOS for the treatment of adults with recurrent respiratory papillomatosis Seven-year period of PAPZIMEOS market exclusivity is effective through August 14,
Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference
08:05am, Tuesday, 26'th May 2026
GERMANTOWN, Md., May 26, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve
Precigen: Why I Am More Cautious After The Q1 Beat (Downgrade)
04:52pm, Thursday, 21'st May 2026
Precigen, Inc. delivered $21.6M in Q1 Papzimeos revenue, aligning with bullish expectations but leaving key launch metrics undisclosed. Management projects cash flow breakeven by year-end, but tight c
Precigen: Full Commercial Validation And Room To Run
09:58am, Thursday, 14'th May 2026
Precigen is recommended as a buy due to PAPZIMEOS's early FDA approval, its commercial validation, and astonishingly quick insurer and physician adoption. PGEN's AdenoVerse platform underpins near-ter
Precigen Q1 Earnings Call Highlights
12:14am, Thursday, 14'th May 2026
Precigen NASDAQ: PGEN reported a sharp increase in first-quarter 2026 revenue as the company's first commercial product, PAPZIMEOS, continued its U.S. launch following FDA approval in August 2025.
Precigen, Inc. (PGEN) Q1 2026 Earnings Call Transcript
10:40pm, Wednesday, 13'th May 2026
Precigen, Inc. (PGEN) Q1 2026 Earnings Call Transcript
Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates
06:36pm, Wednesday, 13'th May 2026
Precigen, Inc. (PGEN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.07 per share a year ago.
Precigen Reports First Quarter 2026 Financial Results and Business Updates
04:05pm, Wednesday, 13'th May 2026
PAPZIMEOS™ launch gaining strong momentum with $21.6 million in net product revenue in the first quarter of 2026 reflecting broad-based uptake across the US Patient hub enrollment continues to gain
